Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ToleroMune HDM in House Dust Mite Allergic Subjects
NCT01008332Phase 2Completed
- Sponsor
- NIOX Group
- Start
- Nov 2009
- Primary completion
- Aug 2010
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of HDM-SPIRE in allergic rhinoconjunctivitis (ARC), sponsored by NIOX Group. Started Nov 2009; status: completed.
02
Drugs
HDM-SPIRE
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01008332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01008332.